Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:developed_drug |
gptkb:Tegsedi
gptkb:Waylivra |
| gptkbp:focusesOn |
rare diseases
cardiometabolic diseases |
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:headquarters_location |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Akcea Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:parentOrganization |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:publiclyTraded |
NASDAQ:AKCA
|
| gptkbp:status |
gptkb:subsidiary
|
| gptkbp:website |
https://www.akceatx.com/
|
| gptkbp:bfsParent |
gptkb:Rachelle_Jacques
gptkb:Waylivra |
| gptkbp:bfsLayer |
7
|